Erenumab (Aimovig®) is indicated for the treatment of migraine in adults who have at least 4 migraine days per month when initiating treatment with Aimovig®.
| NCPE Assessment Process | Ongoing |
| Rapid review received | 19/07/2018 |
| Rapid review completed | 15/08/2018 |
| Rapid Review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of erenumab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 28/08/2018 |
| Pre-submission consultation with Applicant | 24/09/2018 |
| Submission received from Applicant | 22/01/2019 |
| Preliminary review sent to Applicant | 01/04/2019 |
| NCPE assessment re-commenced | 01/05/2019 |
| Factual accuracy sent to Applicant | 31/07/2019 |
| NCPE assessment re-commenced | 06/08/2019 |
| Current status | NCPE assessment ongoing |